KC
MDT icon

Kades & Cheifetz’s Medtronic MDT Stock Holding History

Kades & Cheifetz’s Portfolio MDT Stock Details MDT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,416
Closed -$848K – 110
2024
Q3 		$848K Sell
9,416
-99
-1% -$8.33K 0.49% 50
2024
Q2 		$749K Buy
9,515
+178
+2% +$14.6K 0.47% 49
2024
Q1 		$814K Buy
9,337
+980
+12% +$83.6K 0.52% 46
2023
Q4 		$688K Buy
8,357
+16
+0.2% +$1.22K 0.49% 46
2023
Q3 		$654K Sell
8,341
-8
-0.1% -$670 0.52% 43
2023
Q2 		$736K Sell
8,349
-229
-3% -$19.7K 0.56% 41
2023
Q1 		$692K Buy
8,578
+2,201
+35% +$179K 0.55% 40
2022
Q4 		$496K Buy
+6,377
New +$517K 0.41% 48

Other funds holding MDT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kades & Cheifetz's MDT Position: Q4 2024 in Review

Kades & Cheifetz sold out of Medtronic (MDT) in Q4 2024, closing a stake of 9,416 shares — an estimated $848K sold.

Kades & Cheifetz first reported a position in MDT in Q4 2022 and held it in 8 quarters. The position peaked at $848K in Q3 2024. 2,123 funds tracked by Wall St. Rank hold MDT as of Q4 2024.

  • Kades & Cheifetz reported no remaining Medtronic position as of Q4 2024 after selling out during the quarter.
  • Kades & Cheifetz sold 9,416 Medtronic shares in Q4 2024, an estimated $848K.
  • Kades & Cheifetz first reported a position in Medtronic in Q4 2022 and held it in 8 quarters.
  • Kades & Cheifetz's Medtronic position peaked at $848K in Q3 2024.
  • 2,123 funds tracked by Wall St. Rank held Medtronic as of Q4 2024.

Based on Kades & Cheifetz's 13F filing for Q4 2024, filed 13 Jan 2025.